Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia.
Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom; and.
Alan K
AK
Burnett
Department of Haematology, Nottingham University Hospitals National Health Service Trust, Nottingham, United Kingdom.
Nigel H
NH
Russell
Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom; and.
Robert K
RK
Hills
D000208:Acute Disease; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D003630:Daunorubicin / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D009154:Mutation; D017063:Outcome Assessment, Health Care / Q000379:methods; D016019:Survival Analysis; D020080:Tandem Repeat Sequences / Q000235:genetics; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
D000903:Antibiotics, Antineoplastic; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3; D003630:Daunorubicin